1_NanoSizer_Comparison.jpg
ProFECT Plus: NonCationic-Lipid Nanoparticles for siRNA Encapsulation and Delivery (LSE)

ProFECT Plus: NonCationic-Lipid Nanoparticles for siRNA Encapsulation and Delivery (LSE)

TTLP-016
Regular price
$ 840.00
Sale price
$ 840.00
Buy More Save More

Ask for a Custom Quote: Send Mail

Liposome siRNA Encapsulation (LSE) is a liposome assembly technique to enhance siRNA cargo loading into PEGylated neutral liposomes for improved biocompatibility and pharmacokinetics.  This results in liposomal nanocarriers with efficient nucleic acid encapsulation and enhanced cellular association, while minimizing the cytotoxic effects associated with cationic-mediated transfection. LSE is a quick, easy, reproducible, scalable method for nanoparticle-mediated applied transfection.

Liposome siRNA Encapsulation (LSE) Kit

Description: Liposome siRNA Encapsulation (LSE) is a liposome assembly technique to enhance siRNA cargo loading into PEGylated neutral liposomes for improved biocompatibility and pharmacokinetics.  This results in liposomal nanocarriers with efficient nucleic acid encapsulation and enhanced cellular association, while minimizing the cytotoxic effects associated with cationic-mediated transfection. LSE is a quick, easy, reproducible, scalable method for nanoparticle-mediated applied transfection.

LSE Kit Components:

  • Composite lipid film 
(1mg per rxn)
  • Lipid-based nucleic acid condenser (1 vial per rxn)
  • Injection buffer (EtOH based buffer, 5ml per 10 rxn)
  • Condensing buffer (Tris-HCl based buffer, 10ml per 10 rxn)

Not included in LSE kit:

  • siRNA sequence for desired gene target
  • dialysis cassette/tubing/etc. for liposome purification – OPTIONAL
  • a quantitative measure for siRNA load (i.e. RiboGreen or other)- OPTIONAL

Storage Condition: 4°C for 1 month


Benefits:

  • One step assembly
  • Eradicates the toxicity due to charged liposomes
  • Reduced nucleic acid leakage
  • Enhanced encapsulation efficiency of the siRNA load
  • Improved cellular association
  • Cost-effective

Gene therapy has the potential to attenuate a variety of diseases by altering the molecular pathways leading to pathogenesis.  However, the issue of delivery remains a primary hurdle in the successful translation of gene therapeutics.  Cationic liposomes are beneficial experimental gene vectors due to electrostatic-mediated packaging of nucleic acids.  However, the potential for clinical translation is limited in that cationic liposomes are associated with with reduced biocompatibility and poor pharmacokinetics.  PEGylated neutral liposomes (PLPs), comprised of naturally occurring neutral lipids and surface grafted polyethylene glycol (PEG), are considerably more advantageous in terms of biocompatibility and increased drug stability.  However, the addition of the PEG layer reduces the cell-associative properties of PLPs.  Cell-penetrating peptides can be grafted onto the surface of liposomes to enhance cell delivery in order to overcome this so-called “PEG Dilemma”, but assembly must be controlled to prevent CPP-induced drug leakage.